Day: May 7, 2020

RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%.Consolidated revenues € 429.2 million, +12.1%.EBITDA (1) € 172.9 million, +20.1%Operating income € 148.4 million, +17.8%.Net income € € 111.2 million, + 20.7%Adjusted net income (2) € 125.2 million, +23.5%.Net financial position (3):  net debt of € 880.8 million; € 902.7 million at 31 December 2019.Shareholders’ equity € 1,242.9 million.Isturisa® (osilodrostat) approved in Europe and in the U.S.A., filed for approval in Japan.. Milan, 7 May 2020 – The Board of Directors of Recordati S.p.A. approved the Group’s consolidated results for the first quarter of 2020 prepared in accordance with the recognition and measurement criteria prescribed by the International Financial Reporting Standards (IFRS). These financial statements will be available today at the...

RECORDATI: RISULTATI ECONOMICI IN CRESCITA NEL PRIMO TRIMESTRE DEL 2020. RICAVI +12,1%, EBITDA +20,1%.Ricavi netti consolidati € 429,2 milioni, +12,1%.EBITDA (1) € 172,9 milioni, +20,1%.Utile operativo € 148,4 milioni, +17,8%.Utile netto € 111,2 milioni, + 20,7%.Utile netto rettificato (2) € 125,2 milioni, +23,5%.Posizione finanziaria netta (3): debito netto di € 880,8 milioni; € 902,7 milioni al 31 dicembre 2019.Patrimonio netto € 1.242,9 milioni.Isturisa® (osilodrostat) approvata commercializzazione in Europa e negli Stati Uniti d’America, designazione farmaco orfano confermata. Richiesta autorizzazione presentata in Giappone.Milano, 7 maggio 2020 – Il Consiglio di Amministrazione della Recordati S.p.A. ha approvato, quale rendicontazione finanziaria aggiuntiva su base volontaria (4), la relazione finanziaria al 31 marzo 2020. La relazione...

New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office utilizing blood from a finger prick. Biomerica also announced it is now filling and has shipped commercial orders of its previously announced version of the product to Company distributors who are supplying customers that include NATO, and government agencies in Germany, Switzerland and the Netherlands. The suggested price point of the new high-volume test maintains at $10 per patient price.IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA) today announced it has received a CE mark and launched a new high-volume production version of its COVID-19...

ATLANTA, May 07, 2020 (GLOBE NEWSWIRE) — The Providence Service Corporation (the “Company” or “Providence”) (Nasdaq: PRSC), the nation’s largest provider of non-emergency medical transportation (“NEMT”) programs and holder of a minority interest in Matrix Medical Network, today reported financial results for the three months ended March 31, 2020.First Quarter 2020 Highlights:Revenue from continuing operations of $367.3 millionIncome from continuing operations, net of tax, of $16.3 million, and earnings of $1.02 per diluted common shareAdjusted EBITDA of $16.0 million, Adjusted Net Income of $9.9 million and Adjusted EPS of $0.58Net cash provided by operating activities of $38.8 millionAt March 31, 2020, cash, net of debt, of $92.4 million, compared to $61.4 million at December 31, 2019Subsequent Event:On May 6, 2020, Providence’s...

Significantly Improved Cash Position and Balance SheetClosed Aevi Merger; Transformed into Orphan and Rare Disease BiotechROCKVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced first quarter results for 2020. The Company significantly improved its balance sheet as a result of an appreciation in an investment and as a result of an income tax receivable from the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act which are expected to generate cash proceeds of $15 million in the second quarter ($12.8 million of which has already been realized). “I am extremely proud of the team as we have merged seamlessly across the business.  We are poised...

BANNOCKBURN, Ill., May 07, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2020.Given the merger between HC Group Holdings II, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2019 prospectively. Further, as reported on February 3, 2020, the Company recently completed a reverse 1-for-4 stock split and, as a result, all per share data below is reported incorporating the effect of the reverse stock split as if it was effective for all periods reported.First...

Conference Call and Webcast Today at 8:30 a.m. Eastern TimeALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data ReadoutNEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2020 and recent corporate updates.“While many companies have been greatly hindered by the COVID-19 pandemic, Brainstorm, due to the incredible strength of our clinical trial participants, the amazing teams at our U.S. investigational sites and the talent and commitment of each and every team member at BrainStorm, the Phase 3 ALS trial remains on track for a Q4’20 topline data readout.  Participants in the fully enrolled clinical trial in our 6 United States medical...

ATLANTA, May 07, 2020 (GLOBE NEWSWIRE) — The Providence Service Corporation (“Providence” or the “Company”) (Nasdaq: PRSC) today announced that on May 6, 2020, its subsidiary, LogistiCare Solutions, LLC (“LogistiCare”), acquired National MedTrans, LLC (“National MedTrans”), comprised of its ongoing contractual relationships to provide non-emergency medical transportation (“NEMT”), from Specialty Benefits, LLC.National MedTrans’ contractual relationships, which are primarily capitated, provide more than five million trips annually to approximately two million members on behalf of State Medicaid agencies and managed care organizations across twelve states. “This acquisition advances our relationship with several key payors and adds more than $200 million of estimated annual revenue to LogistiCare’s market-leading platform,” said Dan...

SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI), a leading online entertainment platform for young generations in China, today announced that it will report its first quarter 2020 unaudited financial results on Monday, May 18, 2020, after the close of U.S. markets.The Company’s management will host an earnings conference call at 9:00 PM U.S. Eastern Time on May 18, 2020 (9:00 AM Beijing/Hong Kong time on May 19, 2020). Details for the conference call are as follows:All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, an event passcode, and a unique registrant ID, which will be used to join the conference call.Additionally,...